🔗 Share this article

As the US proceeds with historic revisions to its vaccination recommendations, a particular individual appears in a surprising turn: Høeg, a US-based physician and epidemiologist who initially gained attention by questioning Covid vaccinations in the global health crisis and has concentrated on alleged fatalities following Covid immunization in her recent position at the FDA.

Scheduled Overhauls to Pediatric Vaccine Program

Health officials had intended to reveal major changes to the pediatric vaccine schedule recently, aligning the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US out of step with a large portion of the world with little proof for benefit. The planned update has been postponed until the next year.

Instead of Vinay Prasad, Høeg is set to speak at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the center this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing specific childhood vaccine recommendations in the US in order to be more like the Danish model, a nation with universal health coverage and a population approximately the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccines – usually the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Qualifications

The appointee has no obvious background in drug development, approval processes or management, which has been typical for previous heads of the CBER. She has served at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in leading a major agency. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “be deeply familiar with laws and regulations and the science of medication creation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who headed CBER have had.”

CDER has an immense workload at the FDA, the former commissioner emphasized.

“The public just focuses on the novel medication approvals, but the generic drug division approves a multitude of generic medications. There’s a biosimilars division, over-the-counter program and other areas, and every single one have to be looked after,” she explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative component to the position, which supervises in excess of 5,000 employees. “It’s a enormous management job, if you execute it properly,” Woodcock said.

Response and Controversial Programs

Regarding concerns about Høeg’s credentials and whether this appointment represents greater collaboration among FDA leaders on immunizations, a spokesperson stated that the “questions are based on inaccurate premises”.

“Her resume is consistent with the responsibilities of her job,” the official said, citing the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s new expedited review system, a controversial one-day medication authorization process that apparently concerned her preceding directors. “By what process are these drugs being selected for this expedited pathway? Who takes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards laxer rules of all drugs, except for shots.”

Public Past Work on Vaccines

Concerning immunizations, Høeg has a more documented, if concerning, past, some experts have noted. She published a study using non-validated crowd-sourced reports to determine the frequency of myocarditis following COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the new administration featured altering rules for new vaccines and halting “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Høeg has reportedly proposed excluding young men from receiving Covid vaccines.

“She’s an all-around true believer who starts off with her conclusions and works backwards to fit the science in a very deceptive, untruthful fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|